BioLineRx Ltd. Files 6-K, Incorporates Press Release
Ticker: BLRX · Form: 6-K · Filed: Mar 4, 2024 · CIK: 1498403
Sentiment: neutral
Topics: filing, press-release
TL;DR
BioLineRx filed a 6-K on 3/4/24, attaching a press release. Check that for news.
AI Summary
BioLineRx Ltd. filed a Form 6-K on March 4, 2024, to report the issuance of a press release. The press release, filed as Exhibit 1, is incorporated by reference into the company's effective registration statements. The filing itself does not contain substantive new information beyond the announcement of the press release.
Why It Matters
This filing indicates BioLineRx Ltd. has issued a press release, which may contain important updates for investors regarding company operations or financial performance.
Risk Assessment
Risk Level: low — This filing is primarily procedural, announcing the release of a press release rather than disclosing new material financial or operational information.
Key Players & Entities
- BioLineRx Ltd. (company) — Registrant
- March 4, 2024 (date) — Filing date and press release issuance date
- 001-35223 (other) — SEC File Number
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report the issuance of a press release by BioLineRx Ltd. on March 4, 2024, which is attached as Exhibit 1.
When was this Form 6-K filed?
This Form 6-K was filed on March 4, 2024.
What is incorporated by reference into the company's registration statements?
The press release issued by BioLineRx Ltd. on March 4, 2024, filed as Exhibit 1 to this Form 6-K, is incorporated by reference into all effective registration statements filed by the registrant.
What is the company's principal executive office address?
The company's principal executive office is located at 2 HaMa'ayan Street, Modi'in 7177871, Israel.
Does BioLineRx Ltd. file annual reports under Form 20-F or Form 40-F?
BioLineRx Ltd. files annual reports under cover of Form 20-F.
Filing Stats: 183 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2024-03-04 07:47:21
Filing Documents
- zk2431078.htm (6-K) — 9KB
- exhibit_1.htm (EX-99) — 13KB
- image00001.jpg (GRAPHIC) — 99KB
- 0001178913-24-000792.txt ( ) — 159KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On March 4, 2024, the registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K. The first two paragraphs of the press release attached to this Form 6-K are hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: March 4, 2024